BioMimetic Therapeutics Receives First Orthopedic Marketing Approval For Augment™ Bone Graft |

BioMimetic Therapeutics Receives First Orthopedic Marketing Approval For Augment™ Bone Graft

BioMimetic Therapeutics, Inc ...

BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that it has received approval from Health Canada to begin the marketing of its lead orthopedic product, Augment™ Bone Graft, as an alternative to the use of autograft in midfoot, hindfoot and ankle fusion indications in Canada.

 

http://ow.ly/zlCi

Leave a Reply

Your email address will not be published. Required fields are marked *